CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00 at Barclays

CRISPR Therapeutics (NASDAQ:CRSP - Free Report) had its target price lifted by Barclays from $55.00 to $56.00 in a report issued on Wednesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

Several other analysts have also issued reports on the company. HC Wainwright assumed coverage on CRISPR Therapeutics in a research note on Monday, February 3rd. They issued a "buy" rating and a $65.00 price objective on the stock. Bank of America dropped their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Chardan Capital restated a "buy" rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Royal Bank of Canada restated a "sector perform" rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a research note on Monday, December 30th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, CRISPR Therapeutics has an average rating of "Hold" and an average price target of $74.50.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP traded up $6.23 during trading hours on Wednesday, hitting $49.72. 7,735,783 shares of the company traded hands, compared to its average volume of 1,933,963. The business's 50-day moving average is $41.89 and its 200-day moving average is $46.17. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -17.57 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. Analysts predict that CRISPR Therapeutics will post -5.08 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the sale, the chief executive officer now owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.10% of the company's stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Large investors have recently modified their holdings of the business. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $39,000. Western Pacific Wealth Management LP boosted its holdings in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $43,000. Finally, Eastern Bank acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $70,000. Institutional investors and hedge funds own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.